Economía de los medicamentos genéricos en América Latina

Tobar, Federico
February 2010
Revista Panamericana de Salud Publica;Feb2010, Vol. 27 Issue 2, p59
Academic Journal
In terms of economics, implementing generic drug policy is nothing other than consolidating (or even, creating) drug markets that set competitive prices, the result of which favors public access to essential drugs. This article approaches the topic of generic drugs from the economic perspective by examining various regulatory models in order to evaluate and leverage generic drug policy implementation options as a mechanism for battling some of the markets' specific weaknesses. The conclusion is that there is no single unequivocal method for promoting the use of generic drugs, and that the most favorable way to integrate markets may be through a broad combination of alternatives. These alternatives are grouped and analyzed according to the market issues or challenges that must be overcome. Several options are then identified based on the degree of market consolidation to be obtained.


Related Articles

  • Insurers Praise Bush's Generic Drug Proposal. Brostoff, Steven // National Underwriter / Life & Health Financial Services;10/28/2002, Vol. 106 Issue 43, p3 

    Reports on U.S. President George W. Bush's proposals to increase access to generic drugs. Reactions of insurers and consumer groups; Impact of the proposals on health insurance.

  • EU to Adopt Bolar Provisions In a Victory for Generic Makers. Milmo, Sean // Chemical Market Reporter;02/28/2000, Vol. 257 Issue 9, p6 

    Reports the plan of European producers to change the rules on generic medicines. Information on bolar provision; Terms of the national regulations; Response from active pharmaceutical ingredients producers.

  • Are generic drugs the cure to Medicare's ills? West, Diane // Drug Store News;03/04/2002, Vol. 24 Issue 3, p26 

    Reveals that there is a generic solution to the Medicare drug debate in the U.S., according to the study, 'Greater Use of Generics: A Prescription for Drug Cost Savings.' Conclusion of the study; Type of generic utilization incentive; Study methodology.

  • FDA's Troy cautions generic drugs firms.  // Medical Marketing & Media;Apr2003, Vol. 38 Issue 4, p18 

    Reports on U.S. Food and Drug Administration (FDA) chief counsel Daniel Troy's criticism of the generic drug industry for not supporting the agency's proposed rule on permitting one 30-month stay of approval. Industry's desire to seek legislative changes to the Hatchman-Waxman Act; Internal...

  • Cheap drugs. O'Boyle, Michael // Business Mexico;Sep2002, Vol. 12 Issue 9, p44 

    Reports that the Health Secretariat is driving to push Mexico's regulatory standards for generic drugs up to the level of developed countries. Loophole in regulations that allow generic drugs to be marketed without clinical or laboratory proof that they work the same as the original drugs they...

  • Court blocks FDA regulation, this time on generic drugs.  // Medical Marketing & Media;Feb2000, Vol. 35 Issue 2, p8 

    Reports that the United States Food and Drug Administration (FDA) regulation regarding the approval process for generic drugs has been struck down by the US district court in Washington. Rule that the first manufacturer to seek approval for a generic drug from the FDA gets a 180-day period of...

  • Little Progress Seen for Prescription Drug Plan. Hess, Glenn // Chemical Market Reporter;6/4/2001, Vol. 260 Issue 23, p19 

    Details the hearing conducted before the House Energy and Commerce Health subcommittee about a prescription drug legislation introduced by Representatives Sherrod Brown and Jo Ann Emerson in the United States. Views of Democrat and Republican legislators on the expansion of Medicare...

  • A tragically naive Canadian law for tragically neglected global health. Attaran, Amir // CMAJ: Canadian Medical Association Journal;6/5/2007, Vol. 176 Issue 12, p1726 

    The author reflects on the law passed by Canada's Parliament giving manufacturers of generic drugs to override the patents of brand name drugs for developing countries. He contends on the implementation of the law, which was made in support to the World Trade Organization's medical reform....

  • Canadian Pharmacies Facing Steep Reimbursement Cuts.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p46 

    The article reports on the changes in the reimbursement plans for the pharmaceutical industry in Canada. It highlights the new regulations imposed in Ontario which include prohibition of professional allowances by generic drug manufacturers, establishment of ceilings on the price of generic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics